Daniel Englert, MD
Internal Medicine · New Orleans, LANPI 1891094793
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,562 of the $73,972 with a category attached, or 90.0%. Amgen accounts for 74.1% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $35,870, more than ten times the $303 reported in 2019. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $560.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$55K
- Kyowa Kirin, Inc.$11K
- Ascendis Pharma Endocrinology Inc$6K
- AstraZeneca$919
- Radius Health, Inc.$138
- Boston Scientific$122
- plus $620 from 16 others
What the payments were for
- Consulting fees$9731%
- Speaking & faculty fees$66,56290%
- Travel & lodging$1,7752%
- Food & beverage$4,6626%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 72 | $54,818 |
| Kyowa Kirin, Inc. | 25 | $11,324 |
| Ascendis Pharma Endocrinology Inc | 6 | $6,030 |
| AstraZeneca | 2 | $919 |
| Radius Health, Inc. | 2 | $138 |
| Boston Scientific | 1 | $122 |
| Lilly USA, LLC | 1 | $90 |
| AbbVie(2 entities) | 5 | $88 |
| Johnson & Johnson | 1 | $88 |
| Dexcom, Inc. | 3 | $61 |
| Abbott | 2 | $54 |
| Sequel Med Tech, LLC | 2 | $52 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Averitas Pharma Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $21 |
| Adlon Therapeutics L.p. | 1 | $20 |
| Insulet Corporation | 1 | $18 |
| Medtronic | 1 | $18 |
| BETA Bionics, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,972 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 204 | $258,796 |
| ForteoTeriparatide | 50 | $205,197 |
| OzempicSemaglutide | 134 | $185,697 |
| TrulicityDulaglutide | 87 | $136,970 |
| Teriparatide | 44 | $103,282 |
| TymlosAbaloparatide | 21 | $52,192 |
| JardianceEmpagliflozin | 30 | $36,335 |
| JanuviaSitagliptin Phosphate | 24 | $26,731 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $26,396 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $18,367 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $16,849 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 21 | $16,500 |
| Novolog FlexpenInsulin Aspart | 45 | $14,826 |
| V-Go 20Sub-Q Insulin Device, 20 Unit | 26 | $13,724 |
| Cinacalcet Hcl | 14 | $9,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Trulicity | $90 | $600,962341 claims |
| Novo NordiskOzempic, Novolog | $21 | $193,523162 claims |
| Radius Health, Inc.Tymlos | $138 | $52,19221 claims |
| AbbVieSynthroid | $88 | $6,18956 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in New Orleans
- Steven DeitelzweigNew Orleans$939K
- Jordan GrahamNew Orleans$25K
- Pavan ChavaNew Orleans$24K
- Susan KaramNew Orleans$22K
- Arti ThanguduNew Orleans$20K
- David BrownNew Orleans$17K
- Peter PantlinNew Orleans$13K
- Genevieve MarongeNew Orleans$12K
- Samiullah ArshadNew Orleans$12K
- John WiseNew Orleans$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.